A cohort study of Pemetrexed plus Cisplatin Plus Bevacizumab in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.

A cohort study of Pemetrexed plus Cisplatin Plus Bevacizumab in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer. - A cohort study of Pemetrexed plus Cisplatin Plus Bevacizumab in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009081

Enrollment

Registered

2012-10-15

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirmed non-squamous non-small cell lung cancer. 2)>=20 years old 3)ECOG PS0-2 4)evaluable tumor sites 5)Written informed consent from the patients. 6)Patients who participate in the trial are judged to be appropriate by the attending doctor.

Exclusion criteria

Exclusion criteria: 1)Patient to the appropriate section of the "contraindication ", "contraindications for coadministration" in the attached document bevacizumab, pemetrexed and cisplatin. 2)Have a serious complications. 3)Patients who participate in the trial is judged to be inappropriate by the attending doctor.

Design outcomes

Primary

Measure	Time frame
Progression free Survival	—

Countries

Japan

Contacts

Public ContactYasue Suzaki

Nara Medical University Hospital Second Department of Internal Medicine

Outcome results